PMID- 29637735
OWN - NLM
STAT- MEDLINE
DCOM- 20181126
LR  - 20190221
IS  - 1097-0339 (Electronic)
IS  - 1097-0339 (Linking)
VI  - 46
IP  - 9
DP  - 2018 Sep
TI  - Copy number gain in recurrent anaplastic lymphoma kinase (ALK) rearrangement-lung 
      adenocarcinoma in the pleural effusion.
PG  - 744-747
LID - 10.1002/dc.23936 [doi]
AB  - Copy number gain (CNG), which includes both numerical and structural chromosomal 
      abnormalities, has been investigated in many human cancers. We report a case of 
      recurrence of anaplastic lymphoma kinase (ALK) rearrangement-positive lung 
      adenocarcinoma with increased cellular pleomorphism and ALK copy number in 
      pleural effusion cytology, and retrospectively compared the recurrent tumor with 
      the primary tumor in terms of cytological features, immunohistochemistry (IHC) 
      and fluorescence in situ hybridization (FISH). The patient was a woman in her 50s 
      who was found to have a 20 x 20 mm sized mass in the lung by chest computed 
      tomography (CT), and was diagnosed with ALK rearrangement-positive lung 
      adenocarcinoma. The patient was administered ALK inhibitors, such as alectinib, 
      however 4 years later dissemination to the pleural effusion was detected. The 
      smear was of high cellularity, and a predominant population of large-sized 
      pleomorphic adenocarcinoma cells with prominent nucleoli was observed. On FISH 
      and IHC using cell block material, ALK rearrangement and ALK protein expression 
      were identified again, along with recurrent ALK adenocarcinoma cells, which were 
      observed to have an increased ALK copy number compared with the primary ALK 
      adenocarcinoma cells. On the other hand, there was no discrepancy in the 
      expression of various biomarkers between the primary and corresponding recurrent 
      tumor. The present case showed a marked difference in cytological findings and 
      CNG between the primary and recurrent tumor, indicating that DNA aneuploidy may 
      be related to morphological change such as transformation to bizarre pleomorphic 
      cells in patients receiving alectinib treatment.
CI  - (c) 2018 Wiley Periodicals, Inc.
FAU - Abe, Hideyuki
AU  - Abe H
AUID- ORCID: 0000-0003-0704-8413
AD  - Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.
FAU - Kawahara, Akihiko
AU  - Kawahara A
AUID- ORCID: 0000-0002-4081-2519
AD  - Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.
FAU - Azuma, Koichi
AU  - Azuma K
AD  - Division of Respirology, Neurology and Rheumatology, Department of Internal 
      Medicine, Kurume University School of Medicine, Kurume, Japan.
FAU - Murakami, Yuichi
AU  - Murakami Y
AD  - Department of Pharmaceutical Oncology, Graduate School of Pharmaceutical 
      Sciences, Kyushu University, Fukuoka, Japan.
FAU - Takase, Yorihiko
AU  - Takase Y
AD  - Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.
FAU - Naito, Yoshiki
AU  - Naito Y
AUID- ORCID: 0000-0001-5292-2785
AD  - Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.
FAU - Akiba, Jun
AU  - Akiba J
AD  - Department of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20180410
PL  - United States
TA  - Diagn Cytopathol
JT  - Diagnostic cytopathology
JID - 8506895
RN  - EC 2.7.10.1 (ALK protein, human)
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adenocarcinoma/*genetics
MH  - Adenocarcinoma of Lung
MH  - Amino Acid Sequence
MH  - Anaplastic Lymphoma Kinase
MH  - Base Sequence
MH  - DNA Copy Number Variations/*genetics
MH  - Female
MH  - *Gene Rearrangement
MH  - Humans
MH  - Lung Neoplasms/*genetics
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*genetics/pathology
MH  - Pleural Effusion/*genetics
MH  - Receptor Protein-Tyrosine Kinases/chemistry/*genetics
OTO - NOTNLM
OT  - ALK rearrangement
OT  - copy number gain
OT  - lung cancer
OT  - pleural effusion
OT  - recurrence
EDAT- 2018/04/11 06:00
MHDA- 2018/11/27 06:00
CRDT- 2018/04/12 06:00
PHST- 2017/11/03 00:00 [received]
PHST- 2018/03/03 00:00 [revised]
PHST- 2018/03/22 00:00 [accepted]
PHST- 2018/04/11 06:00 [pubmed]
PHST- 2018/11/27 06:00 [medline]
PHST- 2018/04/12 06:00 [entrez]
AID - 10.1002/dc.23936 [doi]
PST - ppublish
SO  - Diagn Cytopathol. 2018 Sep;46(9):744-747. doi: 10.1002/dc.23936. Epub 2018 Apr 
      10.